KALEO INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KALEO INC, and when can generic versions of KALEO INC drugs launch?
KALEO INC has four approved drugs.
There are thirty-nine US patents protecting KALEO INC drugs.
There are one hundred and forty-four patent family members on KALEO INC drugs in fifteen countries and one supplementary protection certificate in one country.
Summary for KALEO INC
| International Patents: | 144 |
| US Patents: | 39 |
| Tradenames: | 4 |
| Ingredients: | 2 |
| NDAs: | 4 |
Drugs and US Patents for KALEO INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 10,143,792 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 10,960,155 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 10,737,028 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 7,731,686 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | 8,425,462 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | 11,590,286 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | 10,688,244 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for KALEO INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | 8,361,029 | ⤷ Subscribe |
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | 8,608,698 | ⤷ Subscribe |
| Kaleo Inc | NALOXONE HYDROCHLORIDE (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 215457-001 | Feb 28, 2022 | 10,314,977 | ⤷ Subscribe |
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | 10,314,977 | ⤷ Subscribe |
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-001 | Aug 10, 2012 | 8,313,466 | ⤷ Subscribe |
| Kaleo Inc | NALOXONE HYDROCHLORIDE (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 215457-001 | Feb 28, 2022 | 7,918,823 | ⤷ Subscribe |
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | 8,608,698 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for KALEO INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2015255197 | ⤷ Subscribe |
| Israel | 184552 | ⤷ Subscribe |
| United Kingdom | 201109680 | ⤷ Subscribe |
| Japan | 2012508081 | ⤷ Subscribe |
| United Kingdom | 2477046 | ⤷ Subscribe |
| United Kingdom | 2434548 | ⤷ Subscribe |
| Australia | 2011218756 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for KALEO INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
